Food additive sodium benzoate (NaB) activates NFκB and induces apoptosis in HCT116 cells
B Yilmaz, AZ Karabay - Molecules, 2018 - mdpi.com
NaB, the metabolite of cinnamon and sodium salt of benzoic acid is a commonly used food
and beverage preservative. Various studies have investigated NaB for its effects on different …
and beverage preservative. Various studies have investigated NaB for its effects on different …
Combined therapy of ATRA and imatinib mesylate decreases BCR-ABL and ABCB1/MDR1 expression through cellular differentiation in a chronic myeloid leukemia …
CA Pinto, AJS Portilho, MC Barbosa, MEA De Moraes… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disease,
and a major challenge for the eradication of CML is to understand the cause of the …
and a major challenge for the eradication of CML is to understand the cause of the …
Synthesis of novel indol-3-acetamido analogues as potent anticancer agents, biological evaluation and molecular modeling studies
F Doganc, T Ozkan, N Farhangzad, A Mavideniz… - Bioorganic …, 2024 - Elsevier
Cannabinoids bind to cannabinoid receptors CB1 and CB2 and their antitumoral activity has
been reported against some various cancer cell lines. Some synthetic cannabinoids …
been reported against some various cancer cell lines. Some synthetic cannabinoids …
Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms
Y Hekmatshoar, T Özkan… - Cellular and …, 2018 - avesis.ankara.edu.tr
Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by the t (9;
22) and the related oncogene, BCR-ABL. Tyrosine kinase activity of fusion protein BCR-ABL …
22) and the related oncogene, BCR-ABL. Tyrosine kinase activity of fusion protein BCR-ABL …
Identification of exosomal microRNAs and related hub genes associated with imatinib resistance in chronic myeloid leukemia
AZ Karabay, T Ozkan, A Karadag Gurel, A Koc… - Naunyn-Schmiedeberg's …, 2024 - Springer
Chemotherapy resistance is a major obstacle in cancer therapy, and identifying novel
druggable targets to reverse this phenomenon is essential. The exosome-mediated …
druggable targets to reverse this phenomenon is essential. The exosome-mediated …
Some 2‐[4‐(1H‐benzimidazol‐1‐yl) phenyl]‐1H‐benzimidazole derivatives overcome imatinib resistance by induction of apoptosis and reduction of P‐glycoprotein …
Y Hekmatshoar, T Ozkan, M Alp… - Chemical Biology & …, 2023 - Wiley Online Library
Imatinib (IMA) is a tyrosine kinase inhibitor (TKI) introduced for the chronic myeloid leukemia
(CML) therapy. Emergence of IMA resistance leads to the relapse and failure in CML …
(CML) therapy. Emergence of IMA resistance leads to the relapse and failure in CML …
Synthesis of some benzimidazole-derived molecules and their effects on PARP-1 activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 breast cancer cell viability
AS Gurkan-Alp, M Alp, AZ Karabay… - Anti-Cancer Agents …, 2020 - ingentaconnect.com
Background: Poly (ADP-ribosyl) polymerase-1 (PARP-1) inhibitors are compounds that are
used to treat cancers, which are defective in DNA-repair and DNA Damage-Response …
used to treat cancers, which are defective in DNA-repair and DNA Damage-Response …
The evaluation of the anti-cancer effects of Anoectochilus roxburghii on hematological cancers in vitro
BA Gunes, T Ozkan, N Gonulkirmaz, A Sunguroglu - Medical Oncology, 2023 - Springer
The cause of hematological cancers is the uncontrolled proliferation of hematopoietic and
lymphoid tissues, and chemotherapy is used to treat cancer. However, adverse side effects …
lymphoid tissues, and chemotherapy is used to treat cancer. However, adverse side effects …
Methylsulfonylmethane induces caspase‐dependent apoptosis in acute myeloid leukemia cell lines
Y Hekmatshoar, AZ Karabay, T Ozkan… - Fundamental & …, 2024 - Wiley Online Library
Background: Acute myeloid leukemia (AML) is a heterogeneous ailment in both biological
and clinical concepts. Numerous efforts have been devoted to discover natural compounds …
and clinical concepts. Numerous efforts have been devoted to discover natural compounds …
Determination of the apoptotic effect and molecular docking of benzamide derivative XT5 in K562 cells
T Ozkan, Y Hekmatshoar, T Ertan-Bolelli… - Anti-Cancer Agents …, 2018 - ingentaconnect.com
Background: The tyrosine kinase inhibitor, imatinib, used as a first line treatment in Chronic
Myeloid Leukemia (CML) patients, may lead to resistance and failure to therapy. Novel …
Myeloid Leukemia (CML) patients, may lead to resistance and failure to therapy. Novel …